Aparna Kamat Download Headshot

Aparna Kamat, MD

  • Houston Methodist gynecologic oncologist
  • Gynecologic oncologist, Houston Methodist Cancer Center
  • Division of gynecologic oncology chief, Houston Methodist Hospital
Media Contact: Daniel Brown , 832.667.5849

Aparna Kamat, MD

Request Interview
Media Contact: Daniel Brown , 832.667.5849

Areas of Expertise

  • Complex pelvic disease
  • Gynecologic cancer (ovarian, cervical, endometrial
  • Gynecologic surgery

Credentials

BOARD CERTIFICATION
American Board of Obstetrics and Gynecology
Gynecological Oncology
MEDICAL SCHOOL
Seth GS Medical College-Bombay, India | 1994
RESIDENCY
West Virginia University | 2001
INTERNSHIP
West Virginia University | 1997
FELLOWSHIP
Gynecologic Oncology- Houston | 2004

Publications

Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer
VandenHeuvel, SN, Chau, E, Mohapatra, A, Dabbiru, S, Roy, S, O’Connell, C, Kamat, A, Godin, B & Raghavan, SA 2024, , ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.4c00076

Macrophage Activation in the Ovarian Cancer Tumor Microenvironment and Design of a Novel Immunotherapy
OConnell, C, Chau, E, Vasquez, M, VandenHeuvel, S, Kamat, AA, Raghavan , S & Godin, B 2023, , Society of Gynecologic Oncology Winter Meeting, Whistler, Canada, 2/2/23 - 2/4/23.

The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine
O’Connell, C, VandenHeuvel, S, Kamat, A, Raghavan, S & Godin, B 2022, , International journal of molecular sciences, vol. 23, no. 17, 9981. https://doi.org/10.3390/ijms23179981

Ovarian Cancer
Hanafy, AK, Morani, AC, Jensen, CT, Kamat, A, Eifel, PJ & Bhosale, PR 2022, . in Oncologic Imaging: A Multidisciplinary Approach. Elsevier, pp. 452-475. https://doi.org/10.1016/B978-0-323-69538-1.00027-6

Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma (Nature Medicine, (2006), 12, 8, (939-944), 10.1038/nm1447)
Thaker, PH, Han, LY, Kamat, AA, Arevalo, JM, Takahashi, R, Lu, C, Jennings, NB, Armaiz-Pena, G, Bankson, JA, Ravoori, M, Merritt, WM, Lin, YG, Mangala, LS, Kim, TJ, Coleman, RL, Landen, CN, Li, Y, Felix, E, Sanguino, AM, Newman, RA, Lloyd, M, Gershenson, DM, Kundra, V, Lopez-Berestein, G, Lutgendorf, SK, Cole, SW & Sood, AK 2021, , Nature Medicine, vol. 27, no. 12, pp. 2246. https://doi.org/10.1038/s41591-021-01566-5

Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer
Kamat, AA, Fletcher, M, Gruman, LM, Mueller, P, Lopez, A, Landen, CN, Han, L, Gershenson, DM & Sood, AK 2021, , Clinical Cancer Research, vol. 27, no. 15, pp. 4455. https://doi.org/10.1158/1078-0432.CCR-21-2121


Erratum: Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy (Clin Cancer Res (2019) 12(4916–4924)Doi:10.1158/1078-0432.CCR-06-0021)
Halder, J, Kamat, AA, Landen, CN, Han, LY, Lutgendorf, SK, Lin, YG, Merritt, WM, Jennings, NB, Chavez-Reyes, A, Coleman, RL, Gershenson, DM, Schmandt, R, Cole, SW, Lopez-Berestein, G & Sood, AK 2019, , Clinical Cancer Research, vol. 25, no. 10, pp. 3194. https://doi.org/10.1158/1078-0432.CCR-19-1132

Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL
Lyons, YA, Kamat, AA, Zhou, H, Mody, DR, Schwartz, MR, Hobday, C & Ge, Y 2015, , Cancer cytopathology, vol. 123, no. 7, pp. 435-442. https://doi.org/10.1002/cncy.21549

Ovarian Cancer Epidemiology
Bhosale, P, Kamat, A & Eifel, PJ 2012, . in Oncologic Imaging: A Multidisciplinary Approach Expert Consult. Elsevier, pp. 455-478. https://doi.org/10.1016/B978-1-4377-2232-1.00026-7

Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Gillet, JP, Calcagno, AM, Varma, S, Davidson, B, Elstrand, MB, Ganapathi, R, Kamat, AA, Sood, AK, Ambudkar, SV, Seiden, MV, Rueda, BR & Gottesman, MM 2012, , Clinical Cancer Research, vol. 18, no. 11, pp. 3197-3206. https://doi.org/10.1158/1078-0432.CCR-12-0056

Ovarian cancer
Bhosale, P, Kamat, A & Eifel, PJ 2012, . in Oncologic Imaging: A Multidisciplinary Approach. Elsevier Health Sciences, pp. 455-478. https://doi.org/10.1016/B978-1-4377-2232-1.00026-7

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
Coleman, RL, Duska, LR, Ramirez, PT, Heymach, JV, Kamat, AA, Modesitt, SC, Schmeler, KM, Iyer, RB, Garcia, ME, Miller, DL, Jackson, EF, Ng, CS, Kundra, V, Jaffe, R & Sood, AK 2011, , The Lancet Oncology, vol. 12, no. 12, pp. 1109-1117. https://doi.org/10.1016/S1470-2045(11)70244-3

Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors
Liggett, TE, Melnikov, A, Yi, Q, Replogle, C, Hu, W, Rotmensch, J, Kamat, A, Sood, AK & Levenson, V 2011, , Gynecologic oncology, vol. 120, no. 1, pp. 113-120. https://doi.org/10.1016/j.ygyno.2010.09.019

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer
Merritt, WM, Kamat, AA, Hwang, JY, Bottsford-Miller, J, Lu, C, Lin, YG, Coffey, D, Spannuth, W, Nugent, E, Han, LY, Landen, CN, Nick, AM, Stone, RL, Coffman, KT, Bruckheimer, E, Broaddus, R, Gershenson, DM, Coleman, RL & Sood, AK 2010, , Cancer Biology and Therapy, vol. 10, no. 12, pp. 1306-1314. https://doi.org/10.4161/cbt.10.12.13582

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis
Sood, AK, Armaiz-Pena, GN, Halder, J, Nick, AM, Stone, RL, Hu, W, Carroll, AR, Spannuth, WA, Deavers, MT, Allen, JK, Han, LY, Kamat, AA, Shahzad, MMK, McIntyre, BW, Diaz-Montero, CM, Jennings, NB, Lin, YG, Merritt, WM, DeGeest, K, Vivas-Mejia, PE, Lopez-Berestein, G, Schaller, MD, Cole, SW & Lutgendorf, SK 2010, , Journal of Clinical Investigation, vol. 120, no. 5, pp. 1515-1523. https://doi.org/10.1172/JCI40802

Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker
Kamat, AA, Baldwin, M, Urbauer, D, Dang, D, Han, LY, Godwin, A, Karlan, BY, Simpson, JL, Gershenson, DM, Coleman, RL, Bischoff, FZ & Sood, AK 2010, , Cancer, vol. 116, no. 8, pp. 1918-1925. https://doi.org/10.1002/cncr.24997

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer
Merritt, WM, Nick, AM, Carroll, AR, Lu, C, Matsuo, K, Dumble, M, Jennings, N, Zhang, S, Lin, YG, Spannuth, WA, Kamat, AA, Stone, RL, Shahzad, MMK, Coleman, RL, Kumar, R & Sood, AK 2010, , Molecular Cancer Therapeutics, vol. 9, no. 4, pp. 985-995. https://doi.org/10.1158/1535-7163.MCT-09-0967

Frequent downregulation of miR-34 family in human ovarian cancers
Corney, DC, Hwang, CI, Matoso, A, Vogt, M, Flesken-Nikitin, A, Godwin, AK, Kamat, AA, Sood, AK, Ellenson, LH, Hermeking, H & Nikitin, AY 2010, , Clinical Cancer Research, vol. 16, no. 4, pp. 1119-1128. https://doi.org/10.1158/1078-0432.CCR-09-2642

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma
Merritt, WM, Danes, CG, Shahzad, MMK, Lin, YG, Kamat, AA, Han, LY, Spannuth, WA, Nick, AM, Mangala, LS, Stone, RL, Hye, SK, Gershenson, DM, Jaffe, RB, Coleman, RL, Chandra, J & Sood, AK 2009, , Cancer Biology and Therapy, vol. 8, no. 16, pp. 1596-1603. https://doi.org/10.4161/cbt.8.16.9004

Languages

  • English
  • Hindi